# A Study of Mosliciguat in PH-ILD

> **NCT06635850** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pulmovant, Inc.** · enrollment: 135 (actual)

## Conditions studied

- Pulmonary Hypertension
- Interstitial Lung Disease
- Lung Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Fibrosis

## Interventions

- **DRUG:** Mosliciguat
- **DEVICE:** Dry Powder Inhaler
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06635850
- **Lead sponsor:** Pulmovant, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-29
- **Primary completion:** 2026-12
- **Final completion:** 2028-01
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06635850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06635850, "A Study of Mosliciguat in PH-ILD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06635850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*